June 23, 2026 -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its innovative LILRB4/CD3 targeting T Cell Engager (TCE) bispecific antibody (R&D code: 6MW5311), for the treatment of hematologic malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myel

Tinostamustine is being studied in newly diagnosed glioblastoma patients who often face limited treatment options June 24, 2026 -- Knoa Pharma LLC ("Knoa Pharma"), a public health-focused pharmaceutical company, and the Global Coalition for Adaptive Research ("GCAR") announced that the first patient was randomized to the tinostamustine arm on GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment – NCT03970447) in early April. In addition, the first patient in recurrent setting

June 24, 2026 -- REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6). Under the established framework, Stemchymal® will be manufactured by Taiwan-based Steminent

Five migraine presentations will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment, bocunebart Eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, psychological well-being, and workplace productivity Late breaker bocunebart presentation will provide further insight into pituitary adenylate

LTX-002 is a first-in-class antisense oligonucleotide targeting SPTLC1, designed to restore lipid metabolism in the CNS, a novel approach with the potential to address both sporadic and genetic forms of ALS June 23, 2026 -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced that the first participant has been dosed in NeurALS, a Phase 1/2 trial of LTX-002 in adults with amyotrophic lateral sclerosis

June 23, 2026 -- Calico Life Sciences LLC (Calico), a clinical-stage biotechnology organization focused on aging and age-related diseases and founded by Alphabet Inc. and Arthur D. Levinson, today announced that the U.S. Food and Drug Administration (FDA) granted fosigotifator Breakthrough Therapy Designation (BTD) for the treatment of Vanishing White Matter (VWM) disease. Fosigotifator, an investigational eIF2B activator, is currently in a Phase 1b/2 clinical trial evaluating its safety, tolera

First-in-class antibody targeting SMOC2 is the third novel anti-fibrotic program to enter the clinic from Mediar's pipeline Phase 1 study will evaluate safety, tolerability, and pharmacokinetics of novel SMOC2-targeting antibody in healthy volunteers and adults with diabetic kidney disease (DKD) Addition of world-renowned CKD experts to the clinical advisory board (CAB) to help advise Phase 2a development in DKD patients Phase 2a programs for systemic sclerosis (SSc) and idiopathic pulmonary fib

MAVIRET® (glecaprevir/pibrentasvir) is now approved in the European Union for the treatment of acute hepatitis C virus (HCV) infection with compensated liver disease (with or without cirrhosis) in adults and children aged 3 years and older. The approval gives clinicians an option to initiate treatment as soon as acute infection is confirmed, aiming to reduce delays in care and lower the risk of liver disease progression, cirrhosis and liver cancer. As the only treatment approved in the EU for bo

Phase I trial consists of two parts. Part A is a single ascending dose (SAD) study of ASC35 once-monthly Self-Assembling Lipid Depot (SALD) formulation; Part B is a head-to-head study of multiple ascending doses (MAD) of ASC35 once-monthly SALD formulation compared to the U.S. Food and Drug Administration (FDA)-authorized tirzepatide once-weekly formulation. In head-to-head non-human primate (NHP) studies, the average observed half-life of ASC35 was approximately six-fold longer than tirzepatide

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy. In the overall population, sigvotatug vedotin did not show